DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click HERE
to register or log in.
AXL-Targeting Antibody-Drug Conjugate as Novel Therapy for Triple-Negative Breast Cancer
[Technical Report, Annual Report]
UNIVERSITY OF SOUTHERN CALIFORNIA LOS ANGELES
Pagination or Media Count:
[A, Approved For Public Release]